Medical Research Council Acute Myeloid Leukaemia 10 trial who entered complete remission were tissue typed (n ¼ 1063). Four hundred and nineteen had a matched sibling donor and 644 had no match. When compared on a donor versus no donor basis the relapse risk was reduced in the donor arm (36% vs 52%; P ¼ 0AE001) and the disease-free survival (DFS) improved (50% vs 42%; P ¼ 0AE01), but overall survival (OS) was not different (55% vs 50%; P ¼ 0AE1). Sixty-one per cent of patients with a donor underwent transplantation. When patients were subdivided into risk groups based on cytogenetics alone or with the addition of blast response to course 1, a reduction in relapse risk was seen in all risk groups and in three age cohorts (0-14, 15-34 and 35+ years). Significant benefit in DFS was only seen in the intermediate-risk cytogenetic group (50% vs 39%; P ¼ 0AE004). The OS benefit was only seen in intermediate-risk patients (55% vs 44%; P ¼ 0AE02). The reduction in relapse risk in good-risk patients was attributable to patients with t(15;17) and not to patients with t(8;21) or inv(16). Allogeneic transplantation given after intensive chemotherapy was able to reduce relapse in all risk and age groups. However, due to the competing effects of procedural mortality and an inferior response to chemotherapy if relapse does occur, there was a survival advantage only in patients of intermediate risk. This trial found no survival advantage in children, patients over 35 years or good-risk disease.
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Most younger patients (< 60 years) with acute myeloid leukaemia (AML) will enter complete remission with one of several chemotherapy regimens (Mayer et al, 1994; Zittoun et al, 1995; Woods et al, 1996; Hann et al, 1997) . There is, however, no clear agreement on how best to prevent relapse when autologous or allogeneic stem cell transplant and intensive chemotherapy are available. We and others have compared the value of autologous bone marrow transplantation (BMT) in addition to, or as an alternative to, intensive chemotherapy without unanimous agreement that autologous BMT improves overall survival in spite of reducing the risk of relapse (Amadori et al, 1993; Ravindranath et al, 1996; Harousseau et al, 1997; Burnett et al, 1998; Cassileth et al, 1998) . For several years it has been accepted practice to offer allogeneic transplantation if a human leucocyte antigen (HLA)-matched sibling donor was available. This was based on studies conducted in the 1980s which appeared to favour the transplant option (McGlave et al, 1988; Leung et al, 2000) . This choice has become more complicated by the fact that, although the outcome of transplantation has gradually improved, the intensification of post-remission chemotherapy has improved survival considerably such that about 40% of patients will survive more than 5 years from diagnosis (Amadori et al, 1993; Woods et al, 1996; Hann et al, 1997; Cassileth et al, 1998) .
The comparison of allograft with chemotherapy is complicated by the absence of truly randomized comparative studies, and there are only a few studies which use a genetic (or Mendelian) randomization based on donor availability. Two recent studies failed to demonstrate a survival advantage when a donor versus no donor analysis was done (Harousseau et al, 1997; Keating et al, 1998) . A further complication arises from the fact that there are considerable differences between patients in their risk of relapse. Several factors have been identified as predictive of relapse. These include cytogenetics (Grimwade et al, 1998; Keating et al, 1988; Slovak et al, 2000) , response to course 1 of treatment, presenting white blood count, age, FrenchAmerican-British (FAB) type and, most recently, FLt-3 receptor gene mutation (Zittoun et al, 1995; Nakao et al, 1996; Kiyoi et al, 1999; Rombouts et al, 2000) .
Several studies have shown the power of cytogenetic changes in the leukaemic clone to predict relapse. In general, different studies have identified similar risk groups. In our previous report of 1602 cases, mostly aged under 56 years, we defined three risk groups (Grimwade et al, 1998) . Our favourable group, comprising t(15;17), t(8:21), inv16 with or without additional abnormalities, had a relapse risk of 35% at 5 years. An adverse risk group identified by the presence of )5, )7, del(5q), abnormal 3q or complex karyotype -defined as more than four unrelated abnormalities -had a relapse risk of 76%, and the remaining patients including those with a normal karyotype had a relapse risk of 51% at 5 years. The prognosis of acute promyelocytic leukaemia (APL) characterized by t(15:17), who present with a low white blood cell (WBC) count (< 10 · 10 9 /l), has been transformed by the combination of all-trans retinoic acid and chemotherapy, resulting in a low risk of relapse (15%) (Fenaux et al, 1993; Mandelli et al, 1997; Tallman et al, 1997; Burnett et al, 1999a) . A similar, but not identical, classification devised by the South-west Oncology Group (SWOG) resulted in a similarly predictive stratification (Slovak et al, 2000) . We have combined the bone marrow blast response after recovery from course 1, which is an independent predictor of subsequent relapse, with cytogenetics to provide a simple risk score, which has been described in detail and can be used to direct treatment. In the dataset of our AML 10 trial, good-risk patients (28% of all patients) were defined as t(15;17) or FAB M3, t(8;21) or inv(16), irrespective of whether these changes occurred alone or with additional abnormalities and irrespective of morphology after course 1, and had a relapse risk of 33% at 5 years. Poor-risk patients (21% of all patients) were defined as poor-risk cytogenetics or marrow blasts of > 15% 18-23 d after course 1, when the relapse risk was 78%. Intermediate-risk patients (51% of all patients) had standard risk cytogenetics and a < 15% blast count in the bone marrow after course 1. This group had a relapse risk of 50% at 5 years. This risk index has been prospectively validated in 1250 patients in the current Medical Research Council (MRC) AML12 trial (Burnett et al, 1999b) .
Given the paucity of comparative analyses on a donor/no donor basis using an effective chemotherapy schedule, it is important to re-evaluate the role of allogeneic BMT as part of the treatment in first remission of AML, particularly bearing in mind the variable risk of relapse. Here we provide the experience gained in the United Kingdom MRC AML 10 trial which recruited 1966 patients mainly aged under 56 years, between 1988 and 1995, from whom 1063 patients in first complete remission (CR1) with siblings, were tissue typed. . Between May 1988 and April 1995 , 1966 patients were entered into the AML 10 Trial from 163 hospitals in the United Kingdom, Ireland and New Zealand.
PATIENTS AND METHODS

Patients
The trial was open to any patient under 56 years with any form of de novo or secondary AML or refractory anaemia with excess blasts in transformation (RAEB-t). Patients were required to give informed consent under the auspices of each institution's ethical review committee.
Treatment protocol. A major aim of the trial was to evaluate autologous and allogeneic transplantation when added to four courses of intensive chemotherapy. The trial design has been described in detail (Hann et al, 1997; Burnett et al, 1998) . To summarize, patients received four courses of intensive induction and consolidation chemotherapy, after which patients with an HLA-matched sibling donor, who were considered young and fit enough for the procedure, were scheduled to receive a matched sibling allogeneic BMT (allo-BMT), while the remainder could be randomized between autologous BMT (A-BMT) versus no further therapy. The preparative regimen for both allo-BMT and A-BMT was cyclophosphamide 120 mg/kg over 2 d and total-body irradiation (TBI) given either as a single fraction of 750 or 1050 cGy or as eight fractions of 180 cGy (1440 cGy). Children younger than 2 years were prepared with busulphan 16 mg/kg over 4 d and cyclophosphamide 200 mg/kg over 4 d. Supportive care of patients and graft-versus-host disease (GVHD) prophylaxis was according to each institution's protocols.
Towards the end of the trial, evidence emerged suggesting that allo-BMT was not of benefit to good-risk patients, so only a few of these patients entered in 1994 and 1995 received a transplant.
HLA typing. The protocol directed that all patients within the age limit of the regional transplant unit who had a sibling should be tissue typed. If a matched donor was found it was assumed that the patient would receive an allograft in first remission. Those without a donor were eligible to be randomized to have an autologous BMT or no further treatment. The result of this randomization has been reported in full elsewhere . If tissue typing was not done, the reason was recorded.
Risk groups. Cytogenetic characterization was carried out in 41 local laboratories who were monitored in a central quality control scheme (UK, NEQAS, National External Quality Assessment Schemes). Cytogenetic risk groups were defined as favourable, which comprised t(15;17), t(8;21), inv(16) including those with additional abnormalities; adverse, which included )7, )5, del 5q, abn(3q) or complex (defined as a clone with at least five unrelated abnormalities); intermediate, which comprised all other changes and normal karyotype. The relapse risk definitions included information on acute promyelocytic morphology and the percentage of blast cells in the bone marrow 18-23 d after the end of course 1. Good risk was defined as FAB M3 morphology or favourable cytogenetics; poor risk was defined as adverse cytogenetics or > 15% residual blasts in the bone marrow after course 1, except with favourable cytogenetics: standard risk included patients not defined as good or poor risk.
Endpoints. The following definitions were used: overall survival (OS) was the time from achievement of first CR to death; disease-free survival (DFS) was the time from achievement of CR1 to first event (either relapse or death in CR); and relapse risk was the cumulative probability of relapse, censoring at death in CR. A normocellular bone marrow aspirate containing < 5% leukaemic blast cells and showing evidence of normal maturation of other marrow elements was the criterion for the achievement of CR.
Statistical methods. Kaplan-Meier life-tables were constructed for each endpoint and were compared by means of the log-rank test. Surviving patients were censored at 1 May 1999, when follow-up was up-to-date for 98% of patients (the small number of patients lost to follow-up were censored at the date they were last known to be alive). All point estimates quoted for endpoints are at 7 years from CR1 (except for survival from relapse, where they are at 5 years from relapse). Figures in brackets after odds ratios (OR) are the 95% confidence intervals of the OR. An OR less than 1AE0 indicated benefit for the donor group. All P-values are two tailed. All ORs and their associated P-values were adjusted for age group (0-1, 2-14, 15-24, 25-34, 35-44, > 45 years) . In addition to overall analyses, analyses were performed within important prognostic risk groups (good, standard, poor and unknown) and age groups (0-14, 15-34 and > 35 years) and tests for heterogeneity of and/or trend in treatment effect between subgroups were performed. To obtain greater numbers in each age subgroup and therefore greater statistical reliability, analyses are presented in three age groups. All analyses were performed on the Ôintention to treatÕ principle with all patients (donor or no donor) analysed in their allocated arm, irrespective of whether or not transplant was received by patients in the donor group. A Mantel-Byar analysis was used to compare patients with an available donor who had, or did not have, a BMT.
RESULTS
Patient population
Nineteen hundred and sixty-six patients entered the trial of whom 28 were excluded because they were subsequently found not to have AML. Of the remainder, 1609 (83%) achieved remission. The protocol definition of remission required patients to have < 5% blasts in a cellular marrow showing evidence of maturation. Although peripheral blood regeneration was not a requirement, at least 1517 of the 1609 remitters (94%) are known to have achieved 1AE0 · 10 9 /l neutrophils and 100 · 10 9 /l platelets. Of the remainder, 25 recovered neutrophils but not platelets, and five did not recover either before the next treatment course was given; 54 had incomplete information. All patients were platelet and red cell independent. Seven patients were excluded from the analysis as they had BMT before CR was achieved.
Tissue typing
The proportion of patients that were tissue typed was very consistent, at between 84% and 87% of available patients with siblings in each year of the trial. Similarly, the proportion of good-, standard-and poor-risk patients tissue typed did not differ, being 87%, 84% and 90% respectively. Unsurprisingly, there was a significantly reduced level of tissue typing in patients over 35 years (72%) compared with patients < 35 years (98%, P ¼ < 0AE001). This resulted in the median age of typed patients being significantly lower than the untyped group (29 vs 51 years, P ¼ < 0AE001). Five hundred and thirty-eight patients (33%) were not tissue typed for the following reasons: 224 had no sibling, 170 were considered to be too old for transplant, 17 had relapsed or died before tissue typing could be done, 74 for reasons not known, 53 for various known reasons, including goodrisk patients who entered the trial after 1 January 1994 (Fig 1) . The characteristics of the patients are shown in Table I . There were no differences between patients who had a donor, who had no sibling, or who had a sibling(s) but no donor, except that those who had siblings but no donor were more likely to have better cytogenetic risk (P ¼ 0AE04). All analyses compared patients with donors (n ¼ 419) with patients who lacked a donor (n ¼ 868). The analysis was also repeated excluding patients who did not have a sibling, and censoring at transplant (autograft) in the no donor group. Two hundred and eighty-five had favourable cytogenetics (donor 95: no donor 190); 732 had intermediate cytogenetics (donor 239: no donor 493) and 88 had adverse cytogenetics (donor 21; no donor 67). Three hundred and forty-three patients were good risk, 608 were standard risk, 169 were poor risk and 167 were of unknown risk group.
Transplant delivery
All analysis are presented on an intent-to-treat basis. Of the 419 patients with donors available, 39% did not receive related donor transplant in first remission (Table II) . Of the 868 patients with no donor, 200 received an autograft. In 1994 and 1995, the probable lack of benefit of related donor transplant for good-risk patients was becoming clear and the proportion of patients with donors who didn't receive their transplant in first remission increased from 33% for those entered in 1988 to 81% for those entered in 1994/5 protocol. Of the 257 donor patients who were allografted in 38 centres, 214 received cyclophosphamide, combined with TBI in 171 cases. The TBI was fractionated (median of 1440 cGy in eight fractions) in 151 patients and was a single fraction (median dose of 851 cGy/range 720-1050 cGy) in 51 patients. The 43 non-TBI patients usually received cyclophosphamide combined with busulphan. As GVHD prophylaxis, 153 patients received cyclosporine and methotrexate, 49 received cyclosporine, either alone or combined with treatments other than methotrexate (n ¼ 40); 28 patients had T-cell depletion alone. The reasons given for the 162 patients not receiving a transplant were: died or relapsed (33%); refused (22%); good-risk disease (10%); unfit/complications of prior chemotherapy (21%); too old (4%); other (10%).
Treatment outcome
Forty-eight per cent of the 1609 patients who achieved remission on chemotherapy were alive at 7 years from remission with a median follow up of 80 months (range 3-131 months).
Comparison of donor versus no donor groups
Deaths in complete remission. There were twice as many deaths in first remission among donor patients than among no donor patients [19% vs 9%, OR ¼ 2AE08 (1AE49-2AE90), P < 0AE001] (Table III) . Of the 257 patients who received the transplant, 62 (24%) died in first remission, while 17 of the 162 patients (11%) with donors who did not receive the allograft died. In the no donor group, 55 out of 661 (8%) who received chemotherapy only died in 1st remission, and 23 of the 200 who, in addition, received an autograft died (12%). This excess risk of death in 1st remission in the donor group was apparent in all risk groups and in each age group, with no evidence of heterogeneity between the different groups. The majority of deaths (71%) in CR in both groups occurred in the first year, with a further 18% in year two and a few late events. As expected, there was a trend for an increased risk of death in CR with age in the donor group (P ¼ 0AE06), but not in the no donor group (P ¼ 0AE03). This was attributable to the patients who received the allograft (13% aged < 15 years, 21% aged 15-35 years, 37% aged 36+ years died post allograft, P < 0AE001) (Table III) .
Sixty-two patients died in remission after transplant, of which the major causes were: infection 19, haemorrhage 4, infection and haemorrhage 2, GVHD 13, respiratory 7, graft failure 3, other 14.
Relapse risk. The relapse risk was significantly lower in the donor group [36% vs 52% at 7 years, OR ¼ 0AE63 (0AE53-0AE75), P ¼ 0AE0001] (Fig 2) . There was no heterogeneity between risk groups or age group although, as we have reported before, the relapse risk itself was dependent on risk group and, to a lesser extent, age within risk groups. Within the favourable cytogenetic risk group the reduced relapse risk was significant only in the t(15;17) subgroup (22% vs 43%, P ¼ 0AE02) and not by the t(8;21) or inv(16) groups (30% vs 29%; P ¼ 0AE9). As with the deaths in CR, the differences in relapse of the total group were due to the patients who received the transplant.
Disease-free survival (DFS). The competing effects of an excess death rate and reduced relapse risk resulted in a significantly better DFS in the donor group overall [50% vs 42% at 7 years, OR ¼ 0AE82 (0AE70-0AE96), P ¼ 0AE001] (Fig 3) . The tests for heterogeneity within subgroups did not reveal evidence of a significant difference in the effect of donor availability between risk or age groups. However, within the good-risk group there was no evidence of benefit for the t(8;21), inv(16) subgroup, with even a suggestion of harm, although the patient numbers available were small and chance effects could not be excluded.
Outcome after relapse
Of the 130 patients in the donor group who relapsed, 59 (45%) achieved a second remission, compared with 198 of the 420 (47%) in the no donor group. The overall response in the donor group disguises the lower prospect in the patients who relapsed after receiving a transplant compared with those with donors who relapsed without having had a transplant. Of the 41 relapses after transplant, 15 (37%) achieved second CR (CR2), which was partly accounted for by the fact that only 24 were given reinduction chemotherapy. Of the 162 patients who had a donor but did not receive a transplant, 89 relapsed of whom 44(49%) achieved CR2, which is the same as was achieved in the no donor group. The overall survival at 5 years from relapse was 17% in the donor arm, which was not significantly different from that of the 420 patients in the no donor arm who relapsed, who had 15% survival at 5 years from relapse [OR 1AE12 (0AE90-1AE41) P ¼ 0AE3] (Fig 4) . The prospect for survival after relapse was highly dependent on risk and age group. The 5-year survival from relapse was 40% in good-risk patients and 22% in children.
Overall survival (OS).
There was no significant difference in OS at 7 years between the donor group and the no donor group [56% vs 50% at 7 years, OR ¼ 0AE88 (0AE74-1AE04), P ¼ 0AE1]. There was no evidence of a trend for the treatment effect to differ over age groups, but there was some evidence of heterogeneity between risk groups, with significant benefit observed only in the standard-risk group (Fig 5) . If survival is portioned into time periods there was no significant difference in the first year after CR [OR ¼ 1AE23 (0AE95-1AE58), P ¼ 0AE1] (Fig 6) , but for year 2 onwards survival was slightly better in the donor group [OR ¼ 0AE67 (0AE54-0AE84), P ¼ 0AE0005], with a highly significant interaction between the two time periods (P < 0AE0001).
Exclusion of the no sibling or older patients
There were no differences in outcome between the patients with no siblings (n ¼ 224) and those with siblings but no match (n ¼ 644): death in first CR ¼ 8% vs 9% [OR ¼ 0AE82 (0AE49-1AE77), P ¼ 0AE5]; relapse risk ¼ 50% vs 53% at 7 years [OR ¼ 0AE97 (0AE77-1AE21), P ¼ 0AE8]; DFS ¼ 45% vs (80) 69 (20) *Includes allogeneic PBSCT (n ¼ 3) and mismatched related donor BMT (n ¼ 2). All autologous BMT except two autologous PBSCTs, one syngeneic BMT. àAll autologous BMT except four autologous PBSCTs, and seven unrelated donor BMT. 38 (23) 30 (37) 8 (11) 37 (11) 23 (8) 14 (20) *There were no deaths in first complete remission in the donor group following an autologous BMT or syngeneic BMT. Sixty deaths were after allogeneic BMT and two were after allogeneic PBSCT. àTwenty-three deaths were after autologous BMT and two were after unrelated donor BMT.
42% at 7 years [OR
In particular, there was no evidence of a higher early event rate in the no sibling group compared with the no match group: DFS at 3 months from CR was 93% in patients with no siblings and the no match groups [OR ¼ 1AE11 (0AE62-2AE12), P ¼ 0AE6]. When the no sibling group was excluded from the donor/no donor comparison, the results were not altered in any important fashion, with the following ORs: death in CR ¼ 1AE95 (1AE39-2AE74),
Similarly, if the analysis is restricted to patients aged < 45 years, on the grounds that older patients are less likely to be considered suitable for transplant, the results remain fundamentally the same, with the following ORs: death in CR ¼ 2AE26 (1AE58-3AE24), P < 0AE0001; relapse risk ¼ 0AE61 (0AE50-0AE74), P < 0AE0001; DFS ¼ 0AE82 (0AE69-0AE98), P ¼ 0AE03; survival ¼ 0AE88 (0AE73-1AE07), P ¼ 0AE2).
Outcome of patients with donors without BMT
When the donor group is examined, using Mantel-Byar analysis to take account of the time to transplant (but not of potential selection biases), on the basis of whether a transplant was delivered (n ¼ 257) (60%) or was not (n ¼ 162), and with the 13 patients who had another transplant in CR1 censored at the time of the transplant, there was no difference in survival from remission [OR 1AE04, (0AE71-1AE43), P ¼ 1AE0]. The better relapse risk achieved in the transplant group [OR 0AE24, (0AE15-0AE37), P < 0AE0001] was counterbalanced by an increase in deaths in remission [OR 5AE77, (3AE32-10AE04), P < 0AE0001]. These figures were stratified by risk group and age.
DISCUSSION
The survival of younger patients with AML who have been treated with intensive chemotherapy has improved in the last 20 years. Associated with this, it has become much clearer that risk factors can identify groups of patients who are at high or low risk of relapse. These same factors also influence the outcome after relapse. The most important therapeutic issue for younger patients is how to prevent relapse, as the prognosis after relapse for most patients is poor. Allogeneic transplantation became a standard practice for patients who had a sibling donor, although the upper age limit at which any survival advantage was maintained, was less clear. All reports, including this one, have confirmed that this approach remains the best antileukaemic Disease-free survival at 7 years with the odds ratio plots for cytogenetic, risk and age subgroups. Test for heterogeneity showed no significant subgroup heterogeneity. treatment. However, there are several reasons why this may not translate into a better overall survival for patients. In spite of some technical improvements there remains an inevitable procedural mortality, which in this study was 24%. Patients who actually received the transplant may already be a selected group based on the fact that it takes time to deliver post-consolidation treatment and make the administrative arrangements for transplant delivery. During this period patients have the opportunity to relapse, others may develop other toxicities which preclude a safe procedure. As the risk of relapse diminishes with time, those who actually receive the transplant will be at a lower risk of relapse than the entire donor population, making comparison of transplanted patients with a valid control group very difficult. This Ôtime censoringÕ effect has been well described (Gray & Wheatley, 1991) and raised doubts as about the general acceptance of allograft as standard practice for all patients with AML. In our study, 40% of patients who had a matched donor did not receive the transplant. The main reasons were death or relapse prior to undertaking the procedure, the consequences of prior consolidation therapy or patient refusal. Age was a reason for not tissue typing 170 older patients. There was a reduced proportion of transplantation in patients over 35 years who had donors (82/164, 50%) compared with patients under 35 years (175/255, 69%). There was no evidence from this study that there was any overall survival advantage for donor patients aged over 35 years (P ¼ 1AE0). This may be because the higher risk of death in remission (30% vs 16%, P ¼ 0AE0007) in this age group outweighs the reduction in risk of relapse (45% vs 58%, P ¼ 0AE02) more than in younger patients. With the development of low-intensity conditioning protocols it may be possible to exploit the antileukaemic effect with a lower risk of mortality. Although there is insufficient data yet available on the antileukaemic potential of this approach in AML, this would seem to be one of the important issues to prospectively evaluate. Our study would suggest that patients over 35 years are the candidate population.
In order to minimize the time censoring and selection biases, we chose to adopt a donor versus no donor analysis. In the absence of true randomization there does not seem to be an alternative valid way of evaluating allogeneic transplantation. This approach is open to the criticism that it is unreasonable to evaluate a treatment when it was only given to 60% of patients (Frassoni, 2000) . So it must be borne in mind that an intent-to-treat approach can disguise some important underlying effects, the most important being that it will under-represent the antileukaemic effect, but it will also under-represent the impact of excess deaths. In our study it also disguised the fact that attempts to salvage patients who had relapsed from chemotherapy were more successful than in those who relapsed after a transplant was given. As it happens, the survival of the patients who had a donor but did not receive a transplant was not significantly inferior to the patients who had no donor and therefore the same treatment, thus providing no evidence that those not transplanted were poorer risk cases.
The study reported by the EORTC-GIMEMA (European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto) Collaborative Group (Zittoun et al, 1995) , which showed an advantage for allograft, was re-analysed on a donor versus no donor basis and did not show a significant advantage for the donor arm (Keating et al, 1998) . The GOELAM (Groupe Ouest d'Etudes des Leucemies Aigues Myeloblastiques) Trial had a high compliance with allograft and demonstrated a better survival in the donor arm (Harousseau et al, 1997) . Other major trials in adults and children were not analysed on an intent-to-treat basis and tended to show an advantage for the allograft (Amadori et al, 1993; Ravindranath et al, 1996; Cassileth et al, 1998) . All this experience suggests that the value of giving a transplant to all patients in first remission is, at best, uncertain. In this trial there was a modest improvement in survival of 5% at 7 years. In our randomized comparison of autologous BMT we showed similar effects as shown here, i.e. a significant reduction in relapse to some extent compromised by more deaths in CR . We concluded from this that the addition of a fifth treatment course -in this case a transplant -was able to achieve better disease control. The comparison of four versus five courses of treatment is a central question of our current trial (AML12) to which over 1000 patients have been randomized.
A concern in all recent trials has been that many patients who were intended to receive the transplant (autograft or allograft) did not, for various reasons, receive it (Burnett, 1998) . This brings into sharp relief the relatively modest importance of a few per cent advantage in survival if the treatment cannot be given to most patients. In addition, we and the EORTC group showed that allograft had a highly detrimental impact on quality of life (Zittoun et al, 1997; Watson et al, 1999) . This is a particular issue in children and young patients in whom there is important evidence of late toxicity and mortality, and the desire to retain fertility which is more problematic after allograft than chemotherapy (Leiper, 1999; Leung et al, 2000) . One possible way to improve the compliance with transplant, and thereby secure a better antileukaemic opportunity for more patients, would be to deliver it earlier in the treatment schedule. There is little evidence that the use of intensive consolidation before transplant improves the transplant outcome (Tallman et al, 2000) . So while most studies suggest that intensive chemotherapy can match transplant, it might be possible to deliver the transplant much earlier without loss of efficacy so avoiding the toxicity, cost and patient fallout associated with 2-3 courses of intensive consolidation.
Robust prognostic factors have the potential to guide treatment decisions. It is well established that cytogenetics in particular has powerful predictive value irrespective of the treatment used and is also predictive in the context of transplantation (Ferrant et al, 1995; Gale et al, 1995) . This trial is the first attempt to use cytogenetics and an intentto-treat analysis together. Other major trials have attempted to use WBC count, FAB type or achievement of remission in one course as predictors of risk in a donor/no donor analysis (Harousseau et al, 1997; Keating et al, 1998) . We have tested these factors against this trial database and not found them to achieve substantial discrimination of relapse risk (Burnett, 2001) . The SWOG study used a cytogenetic risk classification but not an intent-to-treat analysis (Slovak et al, 2000) . In spite of having some differences in risk group definitions when the SWOG study definitions have been applied to the present study database, the results were very similar in spite of differences in chemotherapy given (Burnett, 2001) . The risk group definitions used in this study were heavily influenced by cytogenetics but also enabled the inclusion of patients with APL morphology but who lacked evidence of (usually for technical reasons) the t(15:17). It also took into account those patients who were resistant to the first course of treatment. Using these, we have attempted to define which risk subgroups benefit or otherwise from transplantation. We have used the conventionally accepted cytogenetic risk groups and our more inclusive risk index, which both gave similar results. The numbers of patients was too small to analyse risk groups by age category but, even allowing for unreliability in such a context, there were no trends to contradict the overall conclusions.
The favourable impact of allograft on relapse was apparent in all risk groups and at all ages. In good-risk patients this was seen in APL patients but was not demonstrable in t(8;21) or inv(16) disease. These data have been superseded in APL by the combination of all-trans retinoic acid with chemotherapy, which is able to deliver a reduction in relapse equivalent to that shown in the donor group but without the excess treatment mortality. It is of interest that there was no reduction in relapse risk in t(8:21)/inv16 patients, which implies that had all the donor group been transplanted there would have been no additional benefit. On the other hand the excess deaths in remission was under-represented, so that if all the donor group had been transplanted, the negative effect of transplant would have been greater. Based on this experience our current trial (AML12) recommends that these good-risk subgroups should not receive a transplant. This decision has been vindicated by the current 5-year survival of 75% in 205 patients treated with chemotherapy alone. Our experience is at odds with the experience reported in the SWOG study in which transplant seemed to benefit the good-risk patients (Slovak et al, 2000) . This might be explained by chance effects due to the relatively smaller number of patients, but more probably because the patients receiving chemotherapy had a much inferior survival (35%) than we observed here. This is supported by the observation that when we applied the SWOG good-risk definition to patients in this trial, our chemotherapy arm delivered a survival of greater than 70% (Burnett, 2001) . Our data strongly support the recommendation that transplantation is not indicated in good-risk patients who can receive intensive chemotherapy. There was some suggestion that the treatment of choice for these patients is high-dose cytosine arabinoside, preferably three courses (Bloomfield et al, 1998; Byrd et al, 1999) , but our consolidation chemotherapy did not include high-dose cytosine arabinoside. Our experience in poor-risk patients was disappointing. We were not able to show a survival benefit in patients defined as adverse risk by cytogenetics or poor risk by including patients refractory to the first course of chemotherapy. This again contradicts the SWOG study, which did show benefit. Our protocol dictated that patients should receive four treatment courses before transplant. This may be unnecessary, and we are currently evaluating the use of allograft in poor-risk patients, delivered as soon as possible after they are identified.
Half of all patients were in the standard-risk group. This was the only subgroup in which the survival benefit was significant (56% vs 45%, P ¼ 0AE02). In the absence of an overall survival benefit, this could be a chance subgroup effect and it would not be valid to conclude that there was definite evidence of benefit. In addition, even in these patients the role of allograft should be kept under review because, since this trial closed, there has been an improvement in the outcome of chemotherapy. The possibility of finding additional prognostic factors in this patient group would be useful. We did not find the presenting WBC count to add predictive value unless it was > 100 · 10 9 /l, and the number of such patients was small, so prospective validation of benefit would be difficult. The recent demonstration that mutations of the FLt3 receptor occur in 20-25% of patients with AML and that this has prognostic value in standard-risk patients, might permit better definition of risk groups for future evaluation of transplant and other treatments. As part of a wider study from our group (Kottaridis et al, 2000) , 264 patients reported here were characterized for this mutation; 62 were positive. Although the presence of the mutation was predictive of relapse and survival, there was no evidence to suggest that allograft influenced the outcome. This question requires a larger study.
The role of allograft in children has been controversial (Woods et al, 1999) . We showed no survival benefit for the 86 children who had a donor, of whom 61 (71%) were transplanted compared with the 229 who did not. Although the patient numbers were small we found no risk subgroup in whom we could recommend allogeneic transplant (data not shown). The Children's Cancer Group recently reported a larger trial in children and adolescents in which there was a high compliance with transplant if a donor was available (Woods et al, 2000) . A significant survival benefit was reported for patients with a donor (60% vs 53%), although there was an over-representation of favourable cytogenetics in the donor arm. It is important to remember that chemotherapy in children continues to achieve improving results, and in our current MRC12 trial the 4-year survival with chemotherapy is 62%.
In conclusion, our trial demonstrates that allogeneic transplant remains the most powerful antileukaemic treatment available, but it was not able to improve survival due to an excess of deaths in remission and a better salvage rate among patients who relapse after chemotherapy. More patients who relapse after chemotherapy can be salvaged. Within risk groups we find no evidence of survival advantage in good-risk patients, or children, or those over the age of 35 years. Although we found no evidence of benefit in poor-risk patients, this would not exclude its potential for benefit if used early or in the absence of suitable alternative treatments. There was a modest but significant survival advantage in the subgroup of standard-risk patients, but even that needs to be interpreted cautiously. In view of the continued improvement of chemotherapy, it is still recommended that transplants for these patients should be given in the context of a prospective trial.
